CSPC Pharmaceutical Group Ltd. said China’s National Medical Products Administration has approved clinical trials in China for its indacaterol acetate and mometasone furoate powder for inhalation. The company said the product is intended as a maintenance treatment for asthma in adults and adolescents aged 12 and older who are not adequately controlled with inhaled corticosteroids and inhaled short-acting beta2-agonists.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260305-12043117), on March 05, 2026, and is solely responsible for the information contained therein.